Connect with us

PR Newswire

Berlin Packaging continues its expansion in the United Kingdom with the acquisition of Raepak Limited

Published

on

MILAN, May 6, 2021 /PRNewswire/ — Berlin Packaging, the world’s largest hybrid packaging supplier, announced today the acquisition of Raepak Limited, a leading supplier of plastic packaging for the cosmetics and personal care end-markets.

Based in Norwich, England, Raepak offers a wide variety of pumps, sprayers, dispensers, airless bottles, tubes, roll-on bottles, and other packaging containers and closures for the beauty industry. Raepak has a wealth of innovation and design experience to complement its product offering, which includes a range of recyclable and eco-friendly packaging.

“The acquisition of Raepak will enable Berlin Packaging to further extend its offering in the cosmetics and personal care sectors,” said Paolo Recrosio, CEO of Berlin Packaging Europe. “Raepak has strong customer and supplier relationships and deep experience in the UK beauty sector, which will create significant business opportunities for our group.”  

“Raepak has experienced incredible growth over the last several years,” said Andrew Paterson, Managing Director of Raepak. “We are thrilled to be joining Berlin Packaging and believe strongly this will benefit our employees, customers, and suppliers.”

“All 14 companies that Berlin Packaging has acquired in Europe and the UK since 2016 add strategic value to our enterprise with their product, geographic, and end-use market expertise,” said Bill Hayes, CEO and President of Berlin Packaging. “Raepak is no exception, given the breadth of their plastic offering, sustainability and design experience, and knowledge of the beauty and personal care sectors in the United Kingdom.”

All Raepak employees and locations will be retained.

Berlin Packaging

Berlin Packaging is the world’s largest Hybrid Packaging Supplier® of glass, plastic, and metal containers and closures. The company supplies billions of items annually along with package design, financing, consulting, warehousing, and logistics services for customers across all industries. Berlin Packaging brings together the best of manufacturing, distribution, and income-adding service providers. Its mission is to increase the net income of its customers through packaging products and services.

See BerlinPackaging.com for more information.

About Bruni Glass, a Berlin Packaging Company

Bruni Glass, the largest packaging distributor in Europe, has 40+ years’ experience supplying premium and specialty glass packaging to the wine, spirits, food, and gourmet markets. Headquartered in Italy and with locations across Europe, Bruni offers thousands of custom-designed products along with popular standard items. The company has a world-class design studio, a network of high-quality manufacturing partners, a team dedicated to thrilling service, and is certified by CISQ-IMQ (Italian Institute for the Quality Mark) to ISO 9001 standards.

See BruniGlass.com for more information.

For more information:

Press Office – Omnicom PR Group Italy
Barbara Papini,
[email protected],
+335 6113555

Ilaria Sala,
[email protected],
+39 335 8112968

Berlin Packaging
Elena Franzetti,
[email protected],
+39 02 48436611,
+39 3401204145

Julie Saltzman,
[email protected],
+1 312 869 7554 for North America

SOURCE Berlin Packaging

Related Links

http://www.BerlinPackaging.com

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/berlin-packaging-continues-its-expansion-in-the-united-kingdom-with-the-acquisition-of-raepak-limited-301285911.html

PR Newswire

Perfect World to pioneer digital culture and creative sector in joint hands with partners

Published

on

As a world’s leading entertainment group, Perfect World proposed “Creative Thinking” strategy, aiming at breaking the barrier of the real world and virtual world, and combining new types of games with traditional industries so as to empower the development of traditional industries and promote digital upgrade of traditional industries as well.

Under the “Creative Thinking” strategy, Perfect World has made significant achievements in its cooperation with enterprises and institutions, such as implanting scenes of the Qinhuai Lantern Fair of Nanjing Confucius Temple into its famous game “Zhuxian,” and the collaboration between its mobile game Chronicle of Infinity and the famous sports brand Peak.

Perfect World CEO Dr. Robert H. Xiao said at the conference that after all the successful cases, Perfect World has been more confident about cross-over cooperation between digital culture industry and traditional industries. He promised that Perfect World will keep exploring to establish a value chain that empowers traditional industries, and incubate more new types of culture content, products, and business models.

In its collaboration with Nianhuawan scenic spot in Wuxi, Perfect World gamified the scenic spots, and brought tourists an immersive experience by combing the scenic spot and the digital world. The move helps the scenic spot to upgrade from service-based economic to experience economy.

“Not only will we explore subdivided fields with partners, but also work as a bridge to promote cross-over cooperation among companies in various fields, so as to achieve common development,” said Dr. Xiao. “And we hope to joint hands with our partners to unlock a new track in this ‘experimental production’ of the culture industry that faces the future,” he added.

Perfect World will tailor a whole set of solutions and plans on digital upgrading partners’ products based on their requirements. For example, in its cooperation with Shanghai Science and Technology Museum, Perfect World will develop a game to turn the complicated scientific knowledge into visions to help readers understand the scientific knowledge. The Group will also have an in-depth cooperation with China Audio-video and Digital Publishing Association in the field of education and vocational training such as e-sports talent cultivation.

The culture department of Beijing’s Dongcheng district, People’s Cultural Tourism of People’s Daily, a cultural & creative institute affiliated to Tsinghua University, Beijing Dongsheng Bozhan Cloud Computing Technology Co., Ltd., and Nianhuawan scenic spot, also signed strategic cooperation agreements with Perfect World in the brand cooperation conference.

SOURCE Perfect World

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/perfect-world-to-pioneer-digital-culture-and-creative-sector-in-joint-hands-with-partners-301311222.html

Continue Reading

PR Newswire

European Hematology Association : la réponse humorale au vaccin Pfizer/BioNTech BNT162b2 est altérée chez les patients recevant un CAR-T ou un traitement immunosuppresseur de haute intensité

Published

on

LA HAYE, Pays-Bas, 12 juin 2021 /PRNewswire/ — Le vaccin Pfizer/BioNTech BNT162b2 a été approuvé pour la prévention de l’infection par le coronavirus 2 du syndrome respiratoire aigu sévère (SRAS-CoV-2) et est recommandé pour les patients immunodéprimés. Cependant, son efficacité et son innocuité chez les patients suivant une thérapie cellulaire immunologique n’ont pas été bien documentées. Dans le cadre de cette étude, nous avons évalué l’efficacité et l’innocuité du vaccin BNT162b2 chez les patients ayant subi une greffe de cellules hématopoïétiques (HCT) et un traitement au récepteur d’antigène chimérique (CAR)-T. Nous avons suivi prospectivement 79 patients vaccinés ayant été activement traités au Centre médical Sourasky de Tel Aviv et surveillé le profil d’innocuité et la réponse immunitaire humorale au vaccin.

Dans l’ensemble, le vaccin a été bien toléré et tous les effets indésirables se sont résorbés en quelques jours, à l’exception d’un rejet de greffe secondaire, qui fait toujours l’objet d’une enquête. Nous avons observé que seulement 36 % des patients ayant reçu un traitement CAR-T ont développé une réponse aux anticorps humoraux comparativement à 81 % des patients ayant subi une TSS allogénique. De plus, les patients atteints d’aplasie des cellules B et ceux ayant reçu le vaccin peu après la perfusion de cellules étaient moins susceptibles de développer des anticorps. Prises ensemble, ces données démontrent que la réponse humorale au vaccin BNT162b2 est significativement altérée chez les patients recevant le CAR-T, par opposition à ceux ayant reçu une TSS allogénique ayant une bonne réponse.

Présentateur : Professeur Ron Ram

Affiliation : Unité BMT, Tel Aviv Sourasky Medical Center, Tel Aviv, Israël

Résumé : #S285 INNOCUITÉ ET EFFICACITÉ DU VACCIN BNT162B2 MRNA COVID-19 CHEZ LES PATIENTS APRÈS UNE THÉRAPIE ALLOGÉNIQUE À BASE DE HCT ET DE CD19 – ÉTUDE DE COHORTE PROSPECTIVE À UN SEUL CENTRE

À propos du congrès annuel de l’AEH : Chaque année, en juin, l’AEH organise son congrès annuel dans une grande ville européenne. Cette année, en raison de la persistance de la pandémie de COVID-19, l’AEH organise pour la deuxième fois un Congrès virtuel. Le Congrès s’adresse aux professionnels de santé travaillant dans le domaine de l’hématologie ou s’y intéressant. Les sujets du programme scientifique vont de la physiologie et du développement des cellules souches à la leucémie, le lymphome, le diagnostic et le traitement, les globules rouges, les globules blancs et les troubles plaquettaires, l’hémophilie et le myélome, la thrombose et les troubles de la coagulation ainsi que la transfusion et la transplantation de cellules souches.

Site web :www.ehaweb.org

Logo – https://mma.prnewswire.com/media/622259/EHA_Logo.jpg

SOURCE European Hematology Association (EHA)

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/european-hematology-association-la-reponse-humorale-au-vaccin-pfizer-biontech-bnt162b2-est-alteree-chez-les-patients-recevant-un-car-t-ou-un-traitement-immunosuppresseur-de-haute-intensite-862309567.html

Continue Reading

PR Newswire

EHA:Eficacia de la vacuna Pfizer/BioNTech BNT162b2 en pacientes que reciben CAR-T

Published

on

– European Hematology Association:La respuesta humoral a la vacuna Pfizer/BioNTech BNT162b2 se ve afectada en pacientes que reciben CAR-T o terapia inmunosupresora de alta intensidad

LA HAYA, Países Bajos, 12 de junio de 2021 /PRNewswire/ — La vacuna Pfizer/BioNTech BNT162b2 ha sido aprobada para la prevención del síndrome respiratorio agudo severo por coronavirus 2 (SARS-CoV-2) y se recomienda para pacientes inmunosuprimidos. Sin embargo, su eficacia y seguridad en pacientes sometidos a terapia celular inmunológica no han sido bien documentadas. En este estudio, evaluamos la eficacia y seguridad de la vacuna BNT162b2 en pacientes que se sometieron a trasplante de células hematopoyéticas (HCT) y terapia con receptor de antígeno quimérico (CAR) -T. Seguimos prospectivamente a 79 pacientes vacunados que fueron tratados activamente en el Centro Médico Sourasky de Tel Aviv y monitoreamos el perfil de seguridad y la respuesta inmune humoral a la vacuna.

En general, la vacuna fue bien tolerada y todos los efectos secundarios se resolvieron en unos pocos días, excepto un rechazo secundario del injerto, que aún está bajo investigación. Observamos que solo el 36% de los pacientes que recibieron terapia CAR-T desarrollaron una respuesta humoral de anticuerpos en comparación con el 81% de los pacientes que se sometieron a un HCT alogénico. Además, los pacientes con aplasia de células B y los que recibieron la vacuna poco después de la infusión de células tenían menos probabilidades de desarrollar anticuerpos. Tomados en conjunto, estos datos demuestran que la respuesta humoral a la vacuna BNT162b2 está significativamente alterada en los pacientes que reciben CAR-T, a diferencia de aquellos después de un HCT alogénico que tuvieron una buena respuesta.

Presentador:  Profesor Ron Ram

Afiliación:  BMT Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Abstract: #S285  SAFETY AND EFFICACY OF THE BNT162B2 MRNA COVID-19 VACCINE IN PATIENTS AFTER ALLOGENEIC HCT AND CD19-BASED CAR-T THERAPY – A SINGLE CENTER PROSPECTIVE COHORT STUDY

Acerca del Congreso anual de EHA: Cada junio, la EHA organiza su Congreso Anual en una de las principales ciudades europeas. Este año, debido a la persistente pandemia de COVID19, EHA organiza un Congreso virtual por segunda vez. El Congreso está dirigido a profesionales de la salud que trabajen o estén interesados en el campo de la hematología. Los temas del programa científico van desde la fisiología y el desarrollo de las células madre hasta la leucemia; linfoma diagnostico y tratamiento; las células rojas de la sangre; trastornos de los glóbulos blancos y las plaquetas; hemofilia y mieloma; trombosis y trastornos hemorrágicos; así como transfusión y trasplante de células madre.

Sitio web: www.ehaweb.org

Logo – https://mma.prnewswire.com/media/622259/EHA_Logo.jpg

SOURCE European Hematology Association (EHA)

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/eha-eficacia-de-la-vacuna-pfizer-biontech-bnt162b2-en-pacientes-que-reciben-car-t-868759422.html

Continue Reading

PR Newswire

European Hematology Association: Overall Survival Benefit Established With Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) in Elderly Patients with Transplant-ineligible Newly Diagnosed Multiple Myeloma (NDMM): Long-Term Interim Analysis of the MAIA Study

Published

on

THE HAGUE, Netherlands, June 12, 2021 /PRNewswire/ — The phase 3 MAIA study evaluated D-Rd versus Rd in 737 patients who were ineligible for high-dose chemotherapy and autologous stem cell transplantation. The primary analysis of MAIA demonstrated a 44% reduction in the risk of disease progression or death after treatment with D-Rd compared with Rd alone. At a median follow-up of almost 5 years (56.2 months), we now report the pre-specified interim overall survival analysis of MAIA.

The addition of daratumumab to Rd treatment significantly reduced the risk of death by 32% (hazard ratio, 0.68; 95% confidence interval [CI], 0.53-0.86; P=0.0013) with an estimated 5-year overall survival rate of 66.3% in the D-Rd group compared with 53.1% in the Rd alone group. These results are despite 46% of patients who received subsequent therapy in the Rd arm receiving daratumumab. Similarly, the significant progression-free survival benefit of D-Rd versus Rd that was identified in the primary analysis was maintained, with a 47% reduction in the risk of disease progression or death (HR, 0.53; 95% CI, 0.43-0.66; P<0.0001) and an estimated 60-month progression-free survival rate of 52.5% versus 28.7%, respectively; these data provide a new PFS benchmark for patients with NDMM who are transplant ineligible. The high overall response rate (93% vs 82%) further demonstrated the added clinical benefit of D-Rd versus Rd alone. No new safety concerns were identified for D-Rd and the most common (>15%) grade 3/4 treatment-emergent adverse events for D-Rd and Rd were neutropenia (54% vs 37%), pneumonia (19% vs 11%), anemia (17% vs 22%), and lymphopenia (16% and 11%). In conclusion, the clinical benefit from the primary analysis of the MAIA study was maintained through 5 years of follow-up and the benefit of upfront D-Rd given to progression was confirmed with a significant OS improvement, further supporting the use of frontline daratumumab as a new standard of care for patients with transplant-ineligible NDMM.

The results of this study will be presented by Prof. Thierry Facon on Saturday, June 12.

Presenter: Professor Thierry Facon

Affiliation: University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France

Abstract: #LB1901 OVERALL SURVIVAL RESULTS WITH DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PHASE 3 MAIA STUDY

About the EHA Annual Congress: Every year in June, EHA organizes its Annual Congress in a major European city. This year due to the persisting COVID19 pandemic, EHA organized a Virtual Congress for the second time. The Congress is aimed at health professionals working in or interested in the field of hematology.

Website: www.ehaweb.org

Logo – http://mma.prnewswire.com/media/622259/EHA_Logo.jpg

SOURCE European Hematology Association (EHA)

Related Links

https://ehaweb.org/

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/european-hematology-association-overall-survival-benefit-established-with-daratumumab-plus-lenalidomide-and-dexamethasone-d-rd-in-elderly-patients-with-transplant-ineligible-newly-diagnosed-multiple-myeloma-ndmm-long-term-in-301310175.html

Continue Reading
Esports5 days ago

Every new Passive Power in Legends of Runeterra Lab of Legends 2.9.0

Crowdfunding4 days ago

April/May 2021 Top Campaigns

Aviation2 days ago

Delta Air Lines Flight Diverts To Oklahoma Over Unruly Off-Duty Flight Attendant

Blockchain4 days ago

Crypto Fund Manager Says Bitcoin ETFs to be Approved By 2022

Esports3 days ago

Lost Ark Founders Pack: Everything You Need to Know

Fintech4 days ago

PayPal launches PayPal Rewards Card in Australia

Cyber Security3 days ago

Data Breach that Impacted Both Audi of America and Volkswagen of America

Energy3 days ago

Industrial robots market in the automotive industry | $ 3.97 billion growth expected during 2021-2025 | 17000+ Technavio Research Reports

Energy3 days ago

Daiki Axis Co., Ltd. (4245, First Section, Tokyo Stock Exchange) Overview of Operating Performance for the First Three Months Ended March 31, 2021

Aviation2 days ago

Spirit Airlines Just Made The Best Argument For Lifting LaGuardia’s Perimeter Rule

Cleantech3 days ago

Tesla Model S 420 Plaid Is The Best Car In The World (But Not For Me)

Fintech5 days ago

Stripe launches Stripe Tax to simplify global tax compliance for Australian businesses

Blockchain4 days ago

Blockchain technology can help to protect sensitive information

Blockchain5 days ago

JPMorgan Cautioned Coming Bear Market Signal in Bitcoin

AI5 days ago

Ransomware Incidents Surging; Cybersecurity Experts Scramble to Respond   

Blockchain3 days ago

Blockchain technology can help to protect sensitive information

Blockchain3 days ago

DCR Technical Analysis: Look for Support Levels of $130.13 and $126.01

CNBC4 days ago

From green energy to cybersecurity, Citi names ‘unstoppable trends’ that investors can jump on

Esports4 days ago

V-Union cards officially revealed for the Pokémon TCG, includes Mewtwo, Zacian, and Greninja

Blockchain4 days ago

State-Chartered Banks in Texas to Provide Crypto Custody

Trending